FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208330629> ?p ?o ?g. }

• W3208330629 endingPage "S106" @default.
• W3208330629 startingPage "S106" @default.
• W3208330629 abstract "Indolent non-Hodgkin lymphomas (iNHL), such as follicular lymphoma (FL) and marginal zone lymphoma (MZL) are highly radiosensitive. Previously untreated patients with localized disease are potentially curable (PC) with RT. While standard of care remains 24Gy, de-escalation to very low dose radiotherapy (VLDRT) of 4Gy reduces toxicities and treatment duration. Use of VLDRT outside of palliation remains controversial, however, we hypothesize it may be sufficient for most lesions.We present the largest single institution VLDRT experience of adults with FL/MZL treated between 2005-2018 with modern principles including PET staging and involved site radiotherapy (ISRT). Outcomes include best clinical/radiographic response using Lugano criteria between 1.5-6 months post-VLDRT, and cumulative incidence of local progression (LP), distant progression and overall progression, all using death as competing risk. Outcomes were stratified by VLDRT intent; lesions considered PC were localized sites without prior treatment. All other sites were considered non-curable. Competing risk regression was used to identify potential histologic/clinical predictors of LP.In total, 250 patients were treated to 299 lesions including 52 potentially curative (PC) sites (Table 1). Post-VLDRT, overall response rate was 90% for all treated sites with 68% achieving complete response (CR). With median follow-up of 2.4y, the 2y cumulative incidence of LP was 25% for the entire cohort. PC patients had considerably lower 2y-LP of 9% (95% CI 3-19%) compared to 29% (95% CI 23-34%) for the non-curable. Lesion size > 6cm was associated with lower odds of CR and greater risk of LP relative to lesions 0-2cm. There was no suggestion of inferior outcomes for PC patients relative to non-curable. The probability of receiving additional RT to the same site 2y post VLDRT is 15% (95% CI 11-19%), and subsequent response after additional RT was 68% CR (n = 30/45), 18% partial response (n = 8), and 14% non-response (n = 6).We demonstrate that modern VLDRT approaches utilizing PET staging and ISRT result in excellent ORR with nearly 70% CR. Importantly, the cumulative incidence of LP at 2 years post VLDRT is low at 25%, highlighting the possibility of durable remissions. Given clinical versatility and apparent efficacy for PC patients, we support an adaptive ISRT stepwise strategy where patients will be treated initially with VLDRT, reserving full dose treatment for those with suboptimal response. A prospective, multicenter study by ILROG has been developed to compare PC patients randomized to standard 24 Gy versus this proposed response-adapted approach." @default.
• W3208330629 created "2021-11-08" @default.
• W3208330629 creator A5000016659 @default.
• W3208330629 creator A5000509600 @default.
• W3208330629 creator A5001663845 @default.
• W3208330629 creator A5007588773 @default.
• W3208330629 creator A5018022811 @default.
• W3208330629 creator A5023759382 @default.
• W3208330629 creator A5043898160 @default.
• W3208330629 creator A5049426344 @default.
• W3208330629 creator A5057053281 @default.
• W3208330629 creator A5058653439 @default.
• W3208330629 creator A5074971164 @default.
• W3208330629 creator A5085812198 @default.
• W3208330629 date "2021-11-01" @default.
• W3208330629 modified "2023-09-25" @default.
• W3208330629 title "Predictors of Response to Very Low Dose Radiotherapy (4Gy) for Indolent B-Cell Lymphomas: Is 4Gy Also Suitable for Potentially Curable Patients?" @default.
• W3208330629 doi "https://doi.org/10.1016/j.ijrobp.2021.07.245" @default.
• W3208330629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700402" @default.
• W3208330629 hasPublicationYear "2021" @default.
• W3208330629 type Work @default.
• W3208330629 sameAs 3208330629 @default.
• W3208330629 citedByCount "0" @default.
• W3208330629 crossrefType "journal-article" @default.
• W3208330629 hasAuthorship W3208330629A5000016659 @default.
• W3208330629 hasAuthorship W3208330629A5000509600 @default.
• W3208330629 hasAuthorship W3208330629A5001663845 @default.
• W3208330629 hasAuthorship W3208330629A5007588773 @default.
• W3208330629 hasAuthorship W3208330629A5018022811 @default.
• W3208330629 hasAuthorship W3208330629A5023759382 @default.
• W3208330629 hasAuthorship W3208330629A5043898160 @default.
• W3208330629 hasAuthorship W3208330629A5049426344 @default.
• W3208330629 hasAuthorship W3208330629A5057053281 @default.
• W3208330629 hasAuthorship W3208330629A5058653439 @default.
• W3208330629 hasAuthorship W3208330629A5074971164 @default.
• W3208330629 hasAuthorship W3208330629A5085812198 @default.
• W3208330629 hasBestOaLocation W32083306291 @default.
• W3208330629 hasConcept C120665830 @default.
• W3208330629 hasConcept C121332964 @default.
• W3208330629 hasConcept C126322002 @default.
• W3208330629 hasConcept C143998085 @default.
• W3208330629 hasConcept C156957248 @default.
• W3208330629 hasConcept C159654299 @default.
• W3208330629 hasConcept C203014093 @default.
• W3208330629 hasConcept C2778453870 @default.
• W3208330629 hasConcept C2778563104 @default.
• W3208330629 hasConcept C2779338263 @default.
• W3208330629 hasConcept C2779921676 @default.
• W3208330629 hasConcept C509974204 @default.
• W3208330629 hasConcept C61511704 @default.
• W3208330629 hasConcept C71924100 @default.
• W3208330629 hasConcept C72563966 @default.
• W3208330629 hasConcept C88879693 @default.
• W3208330629 hasConceptScore W3208330629C120665830 @default.
• W3208330629 hasConceptScore W3208330629C121332964 @default.
• W3208330629 hasConceptScore W3208330629C126322002 @default.
• W3208330629 hasConceptScore W3208330629C143998085 @default.
• W3208330629 hasConceptScore W3208330629C156957248 @default.
• W3208330629 hasConceptScore W3208330629C159654299 @default.
• W3208330629 hasConceptScore W3208330629C203014093 @default.
• W3208330629 hasConceptScore W3208330629C2778453870 @default.
• W3208330629 hasConceptScore W3208330629C2778563104 @default.
• W3208330629 hasConceptScore W3208330629C2779338263 @default.
• W3208330629 hasConceptScore W3208330629C2779921676 @default.
• W3208330629 hasConceptScore W3208330629C509974204 @default.
• W3208330629 hasConceptScore W3208330629C61511704 @default.
• W3208330629 hasConceptScore W3208330629C71924100 @default.
• W3208330629 hasConceptScore W3208330629C72563966 @default.
• W3208330629 hasConceptScore W3208330629C88879693 @default.
• W3208330629 hasIssue "3" @default.
• W3208330629 hasLocation W32083306291 @default.
• W3208330629 hasLocation W32083306292 @default.
• W3208330629 hasOpenAccess W3208330629 @default.
• W3208330629 hasPrimaryLocation W32083306291 @default.
• W3208330629 hasRelatedWork W1983816938 @default.
• W3208330629 hasRelatedWork W1986365036 @default.
• W3208330629 hasRelatedWork W2046728107 @default.
• W3208330629 hasRelatedWork W2079738342 @default.
• W3208330629 hasRelatedWork W2144279718 @default.
• W3208330629 hasRelatedWork W2587612055 @default.
• W3208330629 hasRelatedWork W2790650820 @default.
• W3208330629 hasRelatedWork W2941930761 @default.
• W3208330629 hasRelatedWork W3184484902 @default.
• W3208330629 hasRelatedWork W2439008061 @default.
• W3208330629 hasVolume "111" @default.
• W3208330629 isParatext "false" @default.
• W3208330629 isRetracted "false" @default.
• W3208330629 magId "3208330629" @default.
• W3208330629 workType "article" @default.